Join to access to all OVN content. Join for Free
Field MSL Leadership Panel - MSL QA Session PART ONE with Vanessa Jacobsen, Amy Misnik, and Sue Watson
MSL field leadership aspiring MSLs Medical Affair leaders MSL transition MSL certification

Field MSL Leadership Panel - MSL QA Session PART ONE with Vanessa Jacobsen, Amy Misnik, and Sue Watson


Share This Article


Summary

In this episode, Tom Caravela hosts a panel discussion with guests Sue Watson, Amy Misnik, and Vanessa Jacobson, who share their insights on the MSL role. Sue discusses the best industry experiences for aspiring MSLs and the evolving future of the role post-COVID. Amy offers advice on approaching potential mentors and standing out in interviews, while Vanessa focuses on making an impact as a new MSL and provides guidance for students and new graduates. The episode also touches on the value of MSL certifications. Closing remarks hint at a continuation in a forthcoming part 2.

Today I have Sue Watson, Amy Misnik, and Vanessa Jacobsen joining me for our first ever MSL field leadership panel QA session. They are the first people that came on as guests, the pioneers of the MSL Talk podcast.

In this episode we discuss:

  • For aspiring MSLs with experience mainly in academia, what specific types of industry experiences are best to obtain prior to applying for the first MSL role
  • How does a person approach a potential mentor and how open are Medical Affair leaders to accept this request and what is the eligible criteria for a mentee
  • How can one transition to MSL position and make an impact for the first 3 - 6 months
  • Expecting the role to change in a post-COVID world
  • How does an aspiring MSL stand out vs. a seasoned MSL who’s going through the same rounds of interview
  • Piece of advice if they would go back and give themselves as new graduates 
  • Does certification really give an aspiring or an experienced MSL an advantage

Click for Source
MSL field leadership, aspiring MSLs, Medical Affair leaders, MSL transition, MSL certification

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The ULTIMATE Checklist for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Samantha Buckley

The ULTIMATE Checklist for New MSLs

Podcast
Why Go ALONE? How 2 Aspiring MSLs Reached Their Goal TOGETHER
Partner Avatar MSL Talk: Tom Caravela, Sierra Birch, George Lehman

Why Go ALONE? How 2 Aspiring MSLs Reached Their Goal TOGETHER

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN